Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shubham Pant

Showing results (61-70 of 181) with videos related to

Pageof 19
Sort By:
Cancer|March 18, 2014
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumabShubham Pant, Ludmila K Martin, Susan Geyer, et al.
BMC Cancer|January 4, 2022
PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancerJulia E Douglas, Suyu Liu, Junsheng Ma, et al.
Cancer Investigation|October 14, 2015
A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid TumorsJohanna C Bendell, Suzanne F Jones, Lowell Hart, et al.
Cancer|November 21, 2014
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumorsJohanna C Bendell, Manish R Patel, Jeffrey R Infante, et al.
Journal of Gastrointestinal Oncology|November 18, 2021
Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imagingJane E Rogers, Jonathan D Mizrahi, Graciela M Nogueras Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2018
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced CancerJohanna C Bendell, Anna M Varghese, David M Hyman, et al.
The Oncologist|June 13, 2023
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid TumorsBlessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2023
Adagrasib in Advanced Solid Tumors Harboring a <i>KRAS</i><sup></sup> MutationTanios S Bekaii-Saab, Rona Yaeger, Alexander I Spira, et al.
Journal of Gastrointestinal Cancer|April 29, 2023
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical TrialsRishi Surana, Graciela Nogueras Gonzalez, Jane Rogers, et al.
Journal of Gastrointestinal Cancer|January 18, 2025
Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal AdenocarcinomaEnoch Chang, Alexander D Sherry, Jakob Liermann, et al.
Pageof 19

Showing results (61-70 of 181) with videos related to

Sort By:
Pageof 19
Cancer|March 18, 2014
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumabShubham Pant, Ludmila K Martin, Susan Geyer, et al.
BMC Cancer|January 4, 2022
PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancerJulia E Douglas, Suyu Liu, Junsheng Ma, et al.
Cancer Investigation|October 14, 2015
A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid TumorsJohanna C Bendell, Suzanne F Jones, Lowell Hart, et al.
Cancer|November 21, 2014
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumorsJohanna C Bendell, Manish R Patel, Jeffrey R Infante, et al.
Journal of Gastrointestinal Oncology|November 18, 2021
Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imagingJane E Rogers, Jonathan D Mizrahi, Graciela M Nogueras Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2018
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced CancerJohanna C Bendell, Anna M Varghese, David M Hyman, et al.
The Oncologist|June 13, 2023
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid TumorsBlessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2023
Adagrasib in Advanced Solid Tumors Harboring a <i>KRAS</i><sup></sup> MutationTanios S Bekaii-Saab, Rona Yaeger, Alexander I Spira, et al.
Journal of Gastrointestinal Cancer|April 29, 2023
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical TrialsRishi Surana, Graciela Nogueras Gonzalez, Jane Rogers, et al.
Journal of Gastrointestinal Cancer|January 18, 2025
Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal AdenocarcinomaEnoch Chang, Alexander D Sherry, Jakob Liermann, et al.
Pageof 19